50-52-2 | Thioridazine

Chemical type

• Phenothiazine derivative
• Peroxidase inhibitor (MPO)
• Reversible inhibitor via Compound II accumulation

^[1]

• Phenothiazine antipsychotic drug
• FDA-approved non-antibiotic small molecule

^[2]

Key properties

• Potent inhibitor of PXDN bromination activity (97-99% inhibition at 24 µM)
• IC₅₀ of 1.5 µM in dansylglycine halogenation assay
• Enhances Amplex oxidation without bromide (~50%) but ineffective with bromide
• Good substrate for Compound I but not for Compound II, trapping PXDN in inactive Compound II
• No irreversible inhibition
• Less effective in presence of peroxidase substrates

^[1]

• Moderate binding affinity to CD2068 (Kd ≈ 14.8 µM)
• Inhibits ATPase activity of CD2068 (IC₅₀ ≈ 30 µM)
• Reduces ATP hydrolysis activity significantly
• Antimicrobial activity against multiple Clostridioides difficile ribotypes (MIC 64–128 µg/mL)
• Rapid bactericidal effect (within first hour)
• Additive effect when combined with standard CDI antibiotics
• Capable of modulating gut microbiota composition in vivo

^[2]

• Inhibits PXDN halogenation to modulate oxidative modifications
• Potential for cardiovascular and inflammatory disease models
• Tool for studying peroxidation vs. halogenation cycle diversion

^[1]

• Originally used as an antipsychotic medication
• Investigated as a CD2068 (ABC transporter ATPase) inhibitor
• Adjunct therapy candidate for C. difficile infection (CDI)
• Potential helper compound to enhance antibiotic efficacy
• Potential agent to reverse antibiotic resistance

^[2]

Classification by use

• Reversible enzyme inhibitors
• Inhibitors promoting Compound II accumulation
• MPO-targeted antipsychotics repurposed for peroxidase inhibition

^[1]

• Chemicals used as ABC transporter inhibitors
• Chemicals used to reverse antibiotic resistance

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Peroxidasin Inhibition by Thioridazine and Other Peroxidase Inhibitors, Antioxidants, 2024, 13(1), 23
2. [Cite:2] Repurposing thioridazine as a potential CD2068 inhibitor to mitigate antibiotic resistance in Clostridioides difficile infection, Computational and Structural Biotechnology Journal, Volume 27, 2025, Pages 887-895